NCT01877785

A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAA4549A in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This randomized, double-blind, placebo-controlled, single-ascending dose study will assess the safety, tolerability and pharmacokinetics of ascending doses of MHAA4549A in healthy volunteers. Volunteers will be randomized to receive a single dose of MHAA4549A or matching placebo.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	MHAA4549A	Single-ascending dose of MHAA4549A
DRUG	Placebo	Placebo to MHAA4549A

Timeline

• Start date: 2013-07-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2013-06-14
• Last updated: 2016-11-02

Locations

1 site across 1 country: Canada